JUN 22 2026
Achieve Life Sciences — cytisinicline $ACHV
for nicotine dependence (smoking cessation)
for nicotine dependence (smoking cessation)
Nicotine dependence is a chronic, relapsing disease marked by a compulsive urge to use tobacco despite its harmful health effects, causing millions of preventable deaths each year. Cytisinicline is a partial agonist that activates the same brain receptors as nicotine but with less intensity. By occupying these receptors, it can reduce cravings and withdrawal symptoms, potentially helping people quit smoking.
To evaluate the effectiveness, safety, and cost-effectiveness of cytisine plus behavioural support compared to varenicline plus behavioural support for smoking cessation, in indigenous Māori (or family of Māori) who smoke and are motivated to quit.
Source: ClinicalTrials.gov